| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bio-Rad Laboratories, Inc.$290.83
+0.88 (+0.3%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
7.75 B
EPS
6.11
P/E Ratio
47.37 $
Value Trade
99.51 M
SEC Financials
Q1 2026Dilution Risk
Revenue
592.10 M
R&D Expenses
62.90 M
Operating CF
108.10 M
Total Assets
9.79 B
Total Liabilities
2.94 B
Equity
6.85 B
D/E Ratio
12,345
15.81 %
Week
-6.43 %
1 Month
6.57 %
3 Month
-5.23 %
6 Month
-52.22 %
5 Year
11,159.22 %
All Time
Cash Data
Cash Position
1.56 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
37.63 K
52 Week Range
211.43 - 343.12
% held by Insiders
33.2 %
% held by Institutions
74.82 %
Enterprise Value
7.56 B
Total Shares
21.70 M
Short %
8.32 %
Float Shares
18.10 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 16%
Small Cap (rank 761 of 905)
Percentile RankBio-Rad Laboratories, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BIOBio-Rad to Participate in Upcoming Investor Conferences
Bio-Rad is set to participate in upcoming investor conferences, indicating its ongoing engagement with investors. The participation may provide insights into the company's strategies and future directions. However, specific details about the conferences or presentations were not disclosed in the article.
Read more →BIOBio-Rad Reports First-Quarter 2026 Financial Results
Bio-Rad Laboratories, Inc. reported its first-quarter 2026 financial results, showing a 1.1% increase in net sales year-over-year, despite facing external challenges. The company experienced a significant net loss of $527.1 million, primarily due to changes in the fair market value of its investments. Additionally, Bio-Rad updated its full-year financial outlook, anticipating a potential revenue decline.
Read more →BIOBio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
Bio-Rad Laboratories, Inc. will announce its first-quarter 2026 financial results on April 30, 2026. A conference call is scheduled for the same day at 2:00 PM PT to discuss these results. Investors can participate via phone or a live webcast, with a replay available for a year. Bio-Rad is known for its innovative products in life sciences and diagnostics.
Read more →BIOBio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Bio-Rad Laboratories, Inc. will announce its financial results for Q4 and the full year 2025 on February 12, 2026. A conference call is scheduled for 2:00 PM PT to discuss these results. The company continues to operate as a leader in life science and clinical diagnostics, serving various sectors.
Read more →Competitive Position
How BIO ranks across every disease it competes inCompetitive Position is a premium feature
See how BIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial